P210 - GASTROINTESTINAL SYMPTOMS ARE COMMON IN U.S. PATIENTS WITH MODERATE-SEVERE PSORIASIS
(Room Poster Hall)
19 Jan 18
5:30 PM
-
7:00 PM
Intro/Background: Patients with moderate-to-severe plaque psoriasis (PsO) are at increased risk of developing inflammatory bowel disease (IBD). Aims: A survey was conducted to evaluate the prevalence of gastrointestinal symptoms in PsO patients. Methods: An electronic survey was available to U.S. PsO patients with data collected from Jan-Feb 2017. Patients with moderate-severe plaque PsO and healthy controls (HC), with common co-morbidities allowed in both groups qualified for inclusion in the survey. Psoriasis patients were further categorized as those without recent exposure to biologic therapy (PsO-) vs those with recent (within 4 months) biologic exposure (PsO+). GI symptoms and signs, including frequency and severity, were compared across groups. CalproQuest (CPQ) scores, which have recently been proposed as a tool to identify patients with elevated fecal calprotectin levels and increased risk for IBD, were also calculated. Patients with inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), or other gastrointestinal (GI) diagnoses with symptoms that overlap with IBD were excluded. Results: Overall, 915 patients with self-reported moderate-severe PsO and 1,411 healthy controls participated. Demographics were generally comparable between groups. GI symptoms and signs were significantly more prevalent in the PsO- and PsO+ groups vs the HC group. Pain, fullness/bloating, and diarrhea were more frequent in PsO+ vs PsO- groups(Table). A significantly greater percentage of PsO- and PsO+ patients had positive CPQ scores vs HCs, with the greatest percentage of positive CPQ scores in the PsO+ group(Figure). Conclusion: GI symptoms and signs are common in patients with moderate-to-severe PsO, more so than in healthy controls. This suggests that physicians caring for patients with PsO may consider assessing for GI symptoms and signs, and monitoring for their progression with treatment of PsO to identify patients potentially at risk for developing IBD.